Last reviewed · How we verify
Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy (ALPHAGEM)
Membranous Nephropathy (MN) is a renal autoimmune disease mediated by autoantibodies. Current management is based on the use of immunosuppressive therapies. MN patients with a pro-inflammatory Th17 cytokine profile have a 10.5-fold increased risk of disease relapse. Interferon-based immunomodulatory therapies are effective in blocking the production of cytokines in the Th17 pathway avoiding an increased risk of infection, unlike immunosuppressive treatments. To date, these treatments have not been evaluated in the management of MN. The aims of the ALPHAGEM project are to monitor the immunological activity of the disease before and after 6 months of personalized interferon-alfa treatment in MN patients.
Details
| Lead sponsor | Centre Hospitalier Universitaire de Nice |
|---|---|
| Phase | PHASE2 |
| Status | UNKNOWN |
| Enrolment | 5 |
| Start date | Mon Jul 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Jul 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Membranous Nephropathy
Interventions
- Peginterferon Alfa-2A 180 MCG/ML Injectable Solution
Countries
France